CancerLivER: Biomarker Card

Biomarker Card: Comprehensive information about a biomarker


Biomarker ID 2559
Detailed information
CancerLivER ID2559
Biomarker IL1A,IL1B,IL2,IL12A,IL12B,IL15,IFNG,TNF,IL4,IL5,IL8,IL10,CSF1,ANXA1,HLA-DRA,HLA-DPA1,PRG1
Biomarker Name/Symbol (given in Publication)IL1A,IL1B,IL2,IL12A,IL12B,IL15,IFNG,TNF,IL4,IL5,IL8,IL10,CSF1,ANXA1,HLA-DRA,HLA-DPA1,PRG1
BiomoleculeRNAs
SubjectHuman
Degree of ValidityPrognostic marker for prediction of HCC venous metastases and validated on independent dataset
Experimental ConditionMIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment )
Cancer typeHepatocellular carcinoma
RegulationDiffrentially expressed between MIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment )
Level of significance p < 0.05
SourceTissue
PMID16904609
Type of BiomarkerPrognostic
Pathwayp53-mediated tumor suppres- sive pathway
Cohort115 Asian HCC patients: 52 MIM (primary HCC with venous metastases (major branch of the portal vein or inferior vena cava) or confirmed extrahepatic metastases by follow-up, which we termed a metastasis-inclined microenvironment or MIM) and 63 MAM (HCC without detectable metastases, which we termed
Sensitivity88%
Specificity94%
Accuracy93%
AUCNA
DiseaseMIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment )
Year of Publication2006
Clinical trialNO
Clinical trial (NCT Number)NA

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top